
Opinion|Videos|January 16, 2025
Advancements, Unmet Needs, and Future Trends in the Treatment of NMIBC
Author(s)Mark D. Tyson, II, M.D., M.P.H.
A panelist discusses how significant unmet needs in NMIBC treatment persist around BCG supply shortages, optimal treatment sequencing, biomarker development for patient selection, and reducing treatment toxicity, while expressing optimism about emerging trends in combination therapies, novel delivery systems, and personalized medicine approaches based on molecular profiling.
Advertisement
- What are some unmet needs in the treatment landscape of NMIBC that investigational and approved agents still haven’t addressed?
- What advancements and future trends are you looking forward to in the field, considering the various MOAs of investigational agents?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
EV plus pembro approval reframes first conversation in MIBC diagnosis
3
Ravi Munver, MD, highlights study of first- and second-generation Aquablation systems
4
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
5













